DE60135482D1 - Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen - Google Patents

Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen

Info

Publication number
DE60135482D1
DE60135482D1 DE60135482T DE60135482T DE60135482D1 DE 60135482 D1 DE60135482 D1 DE 60135482D1 DE 60135482 T DE60135482 T DE 60135482T DE 60135482 T DE60135482 T DE 60135482T DE 60135482 D1 DE60135482 D1 DE 60135482D1
Authority
DE
Germany
Prior art keywords
treatment
proliferative diseases
eukaryontic
cell devices
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135482T
Other languages
English (en)
Inventor
Christophe Echeverri
Pierre Goenczy
Anthony Hyman
Steven Jones
Karen Oegema
Matthew Kirkham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenix BioScience GmbH
Original Assignee
Cenix BioScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenix BioScience GmbH filed Critical Cenix BioScience GmbH
Application granted granted Critical
Publication of DE60135482D1 publication Critical patent/DE60135482D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE60135482T 2000-11-09 2001-11-09 Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen Expired - Lifetime DE60135482D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24675000P 2000-11-09 2000-11-09
PCT/EP2001/013034 WO2002038805A2 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
DE60135482D1 true DE60135482D1 (de) 2008-10-02

Family

ID=22932039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135482T Expired - Lifetime DE60135482D1 (de) 2000-11-09 2001-11-09 Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen

Country Status (9)

Country Link
US (1) US7368248B2 (de)
EP (1) EP1334123B1 (de)
JP (1) JP2004526421A (de)
AT (1) ATE405585T1 (de)
AU (2) AU2002224838B9 (de)
CA (1) CA2428438C (de)
DE (1) DE60135482D1 (de)
DK (1) DK1334123T3 (de)
WO (1) WO2002038805A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20070003520A1 (en) * 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
CA2557532A1 (en) 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2980220A1 (de) 2005-09-20 2016-02-03 BASF Plant Science GmbH Verbesserte verfahren zur steuerung der genexpression
BRPI0809130A8 (pt) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Composições combinadas hairpin-antissenso e métodos para modulação da expressão
AR079494A1 (es) 2009-12-18 2012-02-01 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1
EA201201113A1 (ru) 2010-02-10 2013-03-29 Новартис Аг Способы и соединения для роста мышц
EP2632472B1 (de) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) * 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) * 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
CA2428438A1 (en) 2002-05-16
ATE405585T1 (de) 2008-09-15
AU2483802A (en) 2002-05-21
US7368248B2 (en) 2008-05-06
WO2002038805A8 (en) 2007-07-05
US20040048277A1 (en) 2004-03-11
CA2428438C (en) 2012-09-25
WO2002038805A3 (en) 2003-02-13
EP1334123A2 (de) 2003-08-13
JP2004526421A (ja) 2004-09-02
AU2002224838B9 (en) 2007-02-08
DK1334123T3 (da) 2009-01-12
AU2002224838B2 (en) 2006-07-27
WO2002038805A2 (en) 2002-05-16
EP1334123B1 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
DE60135482D1 (de) Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
DE60321458D1 (de) Verwendung von sc6 für die diagnose und behandlung von bustkarzinom
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NZ593388A (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
ATE300288T1 (de) Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
DE602004024037D1 (de) Substituierte heterozyklen
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE60103171D1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
ATE456053T1 (de) Na+, k+-atpase-expression bei zervixdysplasie und krebs
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60327237D1 (de) Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
WO2005025624A3 (en) The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
NO20045556L (no) Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger
WO2005026359A3 (en) The use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition